MiPet Easecto

RSS

sarolaner

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for MiPet Easecto.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use MiPet Easecto.

For practical information about using MiPet Easecto, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 23/02/2018

Authorisation details

Product details
Name
MiPet Easecto
Agency product number
EMEA/V/C/004732
Active substance
sarolaner
International non-proprietary name (INN) or common name
sarolaner
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53BE03
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
30/01/2018
Contact address
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

31/01/2018 MiPet Easecto - EMEA/V/C/004732 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ECTOPARASITICIDES FOR SYSTEMIC USE

Therapeutic indication

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus,Ixodes ricinus and Rhipicephalus sanguineus). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (Demodex canis).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Assessment history

How useful was this page?

Add your rating